Polymyositis and dermatomyositis historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name]. | *In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name]. | ||
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name]. | *In [year], [gene] mutations were first implicated in the pathogenesis of [disease name]. | ||
* | |||
*In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:<ref name="pmid29550929">{{cite journal |vauthors=Leclair V, Lundberg IE |title=New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter |journal=Curr Rheumatol Rep |volume=20 |issue=4 |pages=18 |date=March 2018 |pmid=29550929 |pmc=5857275 |doi=10.1007/s11926-018-0726-4 |url=}}</ref> | *In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:<ref name="pmid29550929">{{cite journal |vauthors=Leclair V, Lundberg IE |title=New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter |journal=Curr Rheumatol Rep |volume=20 |issue=4 |pages=18 |date=March 2018 |pmid=29550929 |pmc=5857275 |doi=10.1007/s11926-018-0726-4 |url=}}</ref> | ||
**Primary idiopathic polymyositis (PM) | **Primary idiopathic polymyositis (PM) | ||
| Line 31: | Line 32: | ||
***Isoleucyl (OJ) | ***Isoleucyl (OJ) | ||
*In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA). | *In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA). | ||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
*In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name]. | *In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:40, 9 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis historical perspective On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis historical perspective |
|
FDA on Polymyositis and dermatomyositis historical perspective |
|
CDC on Polymyositis and dermatomyositis historical perspective |
|
Polymyositis and dermatomyositis historical perspective in the news |
|
Blogs on Polymyositis and dermatomyositis historical perspective |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Historical Perspective
Discovery
- [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
- The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
- In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
- In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
- In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:[1]
- Primary idiopathic polymyositis (PM)
- Primary idiopathic dermatomyositis (DM)
- DM/PM associated with neoplasia
- Childhood DM/PM associated with vasculitis
- DM/PM with associated collagen-vascular disease
- In 1991, Dalakas
- By 1990, seven myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins including
- Helicase protein (Mi2)
- Signal recognition particle (SRP)
- Anti-aminoacyl-tRNA synthetases such as
- Histidyl (Jo1)
- Threonyl (PL-7)
- Alanyl (PL-12)
- Glycyl (EJ)
- Isoleucyl (OJ)
- In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA).
Landmark Events in the Development of Treatment Strategies
- In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
References
- ↑ Leclair V, Lundberg IE (March 2018). "New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter". Curr Rheumatol Rep. 20 (4): 18. doi:10.1007/s11926-018-0726-4. PMC 5857275. PMID 29550929.